XML 110 R96.htm IDEA: XBRL DOCUMENT v3.23.2
Segment Information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)
€ in Millions, $ in Millions
 6 Months Ended 12 Months Ended
Jun. 30, 2023
EUR (€)
Jun. 30, 2022
EUR (€)
Dec. 31, 2022
EUR (€)
Dec. 31, 2022
USD ($)
Disclosure of operating segments [Line Items]        
Net income attributable to non-controlling interests € 26 € 53 € 113  
Fair value remeasurement of contingent consideration (26) (17) 27  
Restructuring costs and similar items (547) (792) (1,336)  
Other gains and losses, and litigation (73) (142) (370)  
Operating income 4,322 3,829 10,656  
Financial expenses (370) (189) (440)  
Financial income 286 34 206  
Income before tax and investments accounted for using the equity method 4,238 3,674 10,422  
Impairment loss on other intangible assets 15 87 (454)  
Immuno Oncology Collaboration Agreement | Regeneron Pharmaceuticals, Inc        
Disclosure of operating segments [Line Items]        
Upfront payments | $       $ 900
Regular milestone payments | $       $ 100
Eloctate        
Disclosure of operating segments [Line Items]        
Impairment loss recognised in profit or loss, intangible assets other than goodwill, reversal amount     2,154  
Other intangible assets | SAR44425        
Disclosure of operating segments [Line Items]        
Impairment loss on other intangible assets     1,586  
Operating segments        
Disclosure of operating segments [Line Items]        
Business operating income 6,059 5,818 13,040  
Material reconciling items        
Disclosure of operating segments [Line Items]        
Share of profit/(loss) from investments accounted for using the equity method (55) (55) (88)  
Net income attributable to non-controlling interests 19 17 33  
Amortization and impairment of intangible assets (1,050) (997) (1,599)  
Fair value remeasurement of contingent consideration (26) (17) 27  
Expense arising from the impact of acquisitions on inventories (5) (3) (3)  
Restructuring costs and similar items (547) (792) (1,336)  
Other gains and losses, and litigation (73) (142) (370)  
Income from out-licensing € 0 € 0 € 952